Mark A. Goldsmith Ph.D.
Net Worth

Last updated:

What is Mark A. Goldsmith Ph.D. net worth?

The estimated net worth of Dr. Mark A. Goldsmith Ph.D. is at least $29,902,814 as of 18 Dec 2024. He owns shares worth $11,877,546 as insider, has earned $13,215,218 from insider trading and has received compensation worth at least $4,810,050 in Revolution Medicines, Inc..

What is the salary of Mark A. Goldsmith Ph.D.?

Dr. Mark A. Goldsmith Ph.D. salary is $962,010 per year as Chief Executive Officer, Pres & Chairman in Revolution Medicines, Inc..

How old is Mark A. Goldsmith Ph.D.?

Dr. Mark A. Goldsmith Ph.D. is 63 years old, born in 1962.

What stocks does Mark A. Goldsmith Ph.D. currently own?

As insider, Dr. Mark A. Goldsmith Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Revolution Medicines, Inc. (RVMD) Chief Executive Officer, Pres & Chairman 325,056 $36.54 $11,877,546

What does Revolution Medicines, Inc. do?

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD logo
RVMD
Revolution Medicines, Inc.
$36.54

Mark A. Goldsmith Ph.D. insider trading

Revolution Medicines, Inc.

Dr. Mark A. Goldsmith Ph.D. has made 52 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 51,611 units of RVMD stock on 29 Sep 2020. As of 18 Dec 2024 he still owns at least 325,056 units of RVMD stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 30,846 $0.49 $15,115
Option
Stock Option (Right to Buy) 30,846 $0.49 $15,115
Sale
Common Stock 11,714 $45.4 $531,862
Sale
Common Stock 50,900 $55.56 $2,827,800
Option
Stock Option (Right to Buy) 36,600 $0.49 $17,934
Option
Common Stock 50,900 $4.09 $208,181
Option
Stock Option (Right to Buy) 50,900 $4.09 $208,181
Option
Common Stock 36,600 $0.49 $17,934
Option
Stock Option (Right to Buy) 9,100 $4.09 $37,219
Sale
Common Stock 9,100 $55.02 $500,718
Sale
Common Stock 10,000 $55.02 $550,240
Option
Common Stock 9,100 $4.09 $37,219
Sale
Common Stock 30,000 $50.36 $1,510,770
Option
Stock Option (Right to Buy) 30,000 $4.09 $122,700
Option
Common Stock 30,000 $4.09 $122,700
Sale
Common Stock 2,022 $45.46 $91,914
Sale
Common Stock 7,978 $44.8 $357,406
Option
Stock Option (Right to Buy) 10,000 $4.09 $40,900
Option
Common Stock 10,000 $4.09 $40,900
Sale
Common Stock 11,715 $44.19 $517,627
Sale
Common Stock 6,783 $45.6 $309,305
Option
Common Stock 10,000 $4.09 $40,900
Sale
Common Stock 3,217 $46.48 $149,520
Option
Stock Option (Right to Buy) 10,000 $4.09 $40,900
Sale
Common Stock 25,000 $45.05 $1,126,200
Sale
Common Stock 10,000 $45.01 $450,120
Option
Common Stock 25,000 $4.09 $102,250
Option
Stock Option (Right to Buy) 25,000 $4.09 $102,250
Sale
Common Stock 11,950 $37.39 $446,775
Sale
Common Stock 900 $39.09 $35,182
Option
Common Stock 7,500 $4.09 $30,675
Sale
Common Stock 5,699 $39.99 $227,880
Sale
Common Stock 901 $40.93 $36,881
Option
Stock Option (Right to Buy) 7,500 $4.09 $30,675
Sale
Common Stock 10,000 $35.34 $353,350
Sale
Common Stock 7,500 $35.48 $266,123
Sale
Common Stock 5,788 $31.58 $182,802
Sale
Common Stock 8,165 $25.9 $211,490
Option
Common Stock 35,000 $0.49 $17,150
Option
Stock Option (Right to Buy) 35,000 $0.49 $17,150
Sale
Common Stock 8,054 $31.31 $252,179
Option
Common Stock 12,007 $1.12 $13,448
Option
Common Stock 17,993 $0.54 $9,716
Option
Stock Option (Right to Buy) 17,993 $0.54 $9,716
Sale
Common Stock 30,000 $35.05 $1,051,560
Sale
Common Stock 10,000 $35.04 $350,410
Option
Stock Option (Right to Buy) 12,007 $1.12 $13,448
Option
Common Stock 45,000 $0.49 $22,050
Option
Stock Option (Right to Buy) 45,000 $0.49 $22,050
Option
Stock Option (Right to Buy) 10,000 $0.49 $4,900
Option
Common Stock 10,000 $0.49 $4,900
Option
Common Stock 10,336 $0.49 $5,065
Option
Stock Option (Right to Buy) 10,336 $0.49 $5,065
Sale
Common Stock 1,023 $18.61 $19,042
Sale
Common Stock 1,571 $24.41 $38,348
Option
Stock Option (Right to Buy) 37,721 $0.49 $18,483
Option
Common Stock 37,721 $0.49 $18,483
Sale
Common Stock 1,531 $30.02 $45,961
Sale
Common Stock 1,485 N/A N/A
Option
Stock Option (Right to Buy) 5,000 $1.12 $5,600
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 15,000 N/A N/A
Option
Stock Option (Right to Buy) 15,000 $1.12 $16,800
Option
Common Stock 15,000 $1.12 $16,800
Option
Stock Option (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 $22.63 $113,155
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Stock Option (Right to Buy) 42,578 N/A N/A
Sale
Common Stock 43,890 N/A N/A
Option
Common Stock 42,578 N/A N/A
Sale
Common Stock 51,611 N/A N/A
Option
Common Stock 30,523 N/A N/A
Option
Stock Option (Right to Buy) 30,523 N/A N/A
Option
Stock Option (Right to Buy) 10,132 N/A N/A
Sale
Common Stock 17,632 N/A N/A
Option
Common Stock 10,132 N/A N/A
Sale
Common Stock 200 $34.02 $6,804
Sale
Common Stock 200 N/A N/A
Option
Stock Option (Right to Buy) 100 N/A N/A
Option
Common Stock 100 N/A N/A
Sale
Common Stock 10,638 N/A N/A
Option
Common Stock 10,097 N/A N/A
Option
Stock Option (Right to Buy) 10,097 N/A N/A
Option
Stock Option (Right to Buy) 29,903 N/A N/A
Sale
Common Stock 41,362 N/A N/A
Option
Common Stock 29,903 N/A N/A
Option
Stock Option (Right to Buy) 7,342 N/A N/A
Sale
Common Stock 8,054 N/A N/A
Option
Common Stock 7,342 N/A N/A
Option
Common Stock 27,363 N/A N/A
Sale
Common Stock 38,651 N/A N/A
Option
Stock Option (Right to Buy) 27,363 N/A N/A
Sale
Common Stock 8,813 N/A N/A
Option
Common Stock 8,813 N/A N/A
Option
Stock Option (Right to Buy) 8,813 N/A N/A
Option
Stock Option (Right to Buy) 2,544 N/A N/A
Sale
Common Stock 6,943 $15.06 $104,562
Sale
Common Stock 6,943 N/A N/A
Option
Common Stock 2,544 N/A N/A
Sale
Common Stock 100 N/A N/A
Option
Stock Option (Right to Buy) 900 N/A N/A
Sale
Common Stock 1,800 N/A N/A
Sale
Common Stock 1,800 $1.12 $2,016
Option
Common Stock 900 N/A N/A
Option
Common Stock 500 N/A N/A
Sale
Common Stock 1,200 N/A N/A
Option
Stock Option (Right to Buy) 500 N/A N/A
Sale
Common Stock 1,900 N/A N/A
Option
Common Stock 1,100 N/A N/A
Option
Stock Option (Right to Buy) 1,100 N/A N/A
Option
Stock Option (Right to Buy) 1,438 N/A N/A
Sale
Common Stock 2,539 N/A N/A
Option
Common Stock 1,438 N/A N/A
Option
Stock Option (Right to Buy) 9,700 N/A N/A
Option
Common Stock 9,700 N/A N/A
Sale
Common Stock 8,368 N/A N/A
Sale
Common Stock 20,684 $26.46 $547,216
Sale
Common Stock 20,684 N/A N/A
Option
Stock Option (Right to Buy) 16,967 N/A N/A
Option
Common Stock 16,967 N/A N/A

Revolution Medicines key executives

Revolution Medicines, Inc. executives and other stock owners filed with the SEC: